Endocrinology Research and Practice
Original Article

Clinical Experience of Insulin Detemir in Turkey: Efficacy and Safety Data From the PREDICTIVE™ Study

1.

Haseki Education and Research Hospital, 4. Internal Medicine Clinic, Istanbul, Turkey

2.

Izmir Ataturk Education and Research Hospital, Endocrinology Clinic, Izmir, Turkey

3.

Haydarpasa Numune Hospital, Diabetes Outpatient Clinic, Istanbul, Turkey

4.

Sait Ciftci Public Health Center, Istanbul, Turkey

5.

Novo Nordisk, Medical Department, Istanbul, Turkey

Endocrinol Res Pract 2008; 12: 91-96
Read: 2214 Downloads: 698 Published: 01 December 2008

Abstract
Objective:
To assess outcomes in Turkish type 1 and 2 diabetic patients given insulin detemir in the multinational PREDICTIVE™ study.
Materials and Methods: PREDICTIVE™ was a large, open-label, prospective, observational study examining the efficacy and safety of insulin detemir in routine clinical practice. Data from the Turkish cohort (2786 patients) were analysed following a 12-week treatment period.
Results: Following treatment, HbA1c significantly decreased by-1.81% (from 9.66%) in type 1 diabetics and by-1.77% (from 9.54%) in type 2 diabetics (P<0.0001). Mean fasting blood glucose (FBG) reduced from 12.35 mmol/L (222.3 mg/dL) to 8.10 mmol/L (145.8 mg/dL) in type 1 diabetics and from 13.46 mmol/L (242.3 mg/dL) to 8.05 mmol/L (144.9 mg/dL) in type 2 diabetics (P<0.0001). Mean within-patient variability of FBG was also reduced (P<0.0001). Serious adverse drug reactions occurred in four patients, 38 if including major hypoglycaemia. Total, major and nocturnal hypoglycaemic events all reduced in frequency after 12 weeks (P<0.0001).
Conclusions: Insulin detemir treatment for 12 weeks resulted in improved, more predictable glycaemic control, modest weight loss or minimal weight gain, and reduced incidence of hypoglycaemia in a large cohort of Turkish patients with diabetes treated according to local clinical practice. 

 

Files
EISSN 2822-6135